How have QBIO shares performed in 2024?

Q BioMed's stock was trading at $0.0004 at the beginning of 2024. Since then, QBIO stock has decreased by 50.0% and is now trading at $0.0002. View the best growth stocks for 2024 here .

When is Q BioMed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Sunday, May 26th 2024. View our QBIO earnings forecast .

How were Q BioMed's earnings last quarter?

Q BioMed Inc. (OTCMKTS:QBIO) posted its earnings results on Wednesday, July, 14th. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.04. The company had revenue of $0.05 million for the quarter.

What other stocks do shareholders of Q BioMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Q BioMed investors own include NVIDIA (NVDA) , Micron Technology (MU) , Washington Trust Bancorp (WASH) , Nokia Oyj (NOK) , Cisco Systems (CSCO) , Inovio Pharmaceuticals (INO) , Intel (INTC) , OPKO Health (OPK) and AT&T (T) .

How do I buy shares of Q BioMed?

Shares of QBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:QBIO

Q BioMed (QBIO) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free QBIO Stock Alerts

$0.0002

0.00 (0.00%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.0002
▼
$0.0002
50-Day Range: N/A
52-Week Range: $0.0001
▼
$0.0155

Volume: N/A
Average Volume: 538 shs
Market Capitalization: $29,020.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Earnings Financials SEC Filings

Get Q BioMed alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Q BioMed Stock (OTCMKTS:QBIO)

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

QBIO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

QBIO Stock News Headlines

March 11, 2024 | msn.com

Clearside Biomedical Q4 2023 Earnings Preview

February 24, 2024 | benzinga.com

Q BioMed Stock (OTC:QBIO) Dividends: History, Yield and Dates

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

February 13, 2024 | msn.com

Biogen Inc. (BIIB) Lags Q4 Earnings and Revenue Estimates

January 28, 2024 | msn.com

Bioxyne’s Q2 FY24 revenue surpasses $2.5m on Aussie medicinal cannabis growth

November 16, 2023 | morningstar.com

Q BioMed Inc QBIO

August 18, 2023 | seekingalpha.com

QBIO Q BioMed Inc.

April 14, 2023 | proactiveinvestors.com

Q BioMed receives US patent and notice of allowance in Europe for Uttroside B; seeks ways to boost shareholder value

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

April 14, 2023 | finance.yahoo.com

Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe

March 3, 2023 | benzinga.com

Q BioMed Stock (OTC:QBIO), Quotes and News Summary

February 10, 2023 | proactiveinvestors.com

Q BioMed gets notice of allowable US patent for liver cancer treatment Uttroside B

February 10, 2023 | finance.yahoo.com

Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Office

January 12, 2023 | benzinga.com

Short Volatility Alert: Q Biomed Inc

January 1, 2023 | finance.yahoo.com

Q BioMed Inc. (QBIO)

November 14, 2022 | proactiveinvestors.com

Q BioMed boosted by multi-million dollar asset as it converts long-term royalty into equity stake in Mannin Research

November 14, 2022 | finance.yahoo.com

Q BIOMED ANNOUNCES ADDITION OF MULTI-MILLION DOLLAR ASSET VALUE WITH EQUITY STAKE IN MANIIN RESEARCH INC.

October 11, 2022 | prnewswire.com

Q BIOMED PROVIDES SHAREHOLDER UPDATE

September 27, 2022 | proactiveinvestors.com

Q Biomed announces patent for groundbreaking GDF15 biomarker for glaucoma detection and treatment

September 27, 2022 | finance.yahoo.com

Q BIOMED ANNOUNCES ISSUANCE OF PATENT FOR GROUNDBREAKING GDF15 BIOMARKER

August 25, 2022 | finance.yahoo.com

Traders News Source Senior Editor Mark Roberts Interviews Denis D Corin, CEO and Chairman Q BioMed Inc.

July 29, 2022 | finance.yahoo.com

Q BioMed Inc. Provides Update to Shareholders

July 26, 2022 | proactiveinvestors.com

Q BioMed welcomes study that highlights the safety and efficacy of Uttroside-B chemotherapeutic

July 26, 2022 | finance.yahoo.com

Q BioMed announces publication of pre-clinical research showing superior safety and efficacy against current first line therapy of its drug candidate Uttroside-B for liver cancer

May 11, 2022 | investing.com

Q BioMed Inc (QBIO)

May 6, 2022 | proactiveinvestors.com

Q BioMed says its strategy is paying off as it outlines its value proposition in multibillion-dollar markets

May 6, 2022 | finance.yahoo.com

Q BioMed Outlines Strategy and Value Proposition in Multi-Billion Dollar Markets

See More Headlines

Receive QBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Q BioMed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 7/14/2021
Today: 4/19/2024
Next Earnings (Estimated): 5/26/2024
Fiscal Year End: 11/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:QBIO
Previous Symbol: NASDAQ:QBIO
CUSIP: N/A
CIK: 1596062
Web: www.qbiomed.com
Phone: (646) 889-2226
Fax: N/A
Employees: 3
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $280,000.00
Price / Sales: 0.10
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.11) per share
Price / Book: 0.00

Miscellaneous

Outstanding Shares: 145,100,000
Free Float: 104,178,000
Market Cap: $29,020.00
Optionable: Not Optionable
Beta: 1.72

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. Denis D. Corin (Age 51)
Chairman, CEO & President
Comp: $300k
Mr. William S. Rosenstadt (Age 56)
Chief Legal Officer, General Counsel & Director
Comp: $300k

Key Competitors

View All Competitors

QBIO Stock Analysis - Frequently Asked Questions

How have QBIO shares performed in 2024?: Q BioMed's stock was trading at $0.0004 at the beginning of 2024. Since then, QBIO stock has decreased by 50.0% and is now trading at $0.0002.
View the best growth stocks for 2024 here.
When is Q BioMed's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Sunday, May 26th 2024.
View our QBIO earnings forecast.
How were Q BioMed's earnings last quarter?: Q BioMed Inc. (OTCMKTS:QBIO) posted its earnings results on Wednesday, July, 14th. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.04. The company had revenue of $0.05 million for the quarter.

What other stocks do shareholders of Q BioMed own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Q BioMed investors own include NVIDIA (NVDA), Micron Technology (MU), Washington Trust Bancorp (WASH), Nokia Oyj (NOK), Cisco Systems (CSCO), Inovio Pharmaceuticals (INO), Intel (INTC), OPKO Health (OPK) and AT&T (T).
How do I buy shares of Q BioMed?: Shares of QBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:QBIO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial